Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer
Sponsor: Dana-Farber Cancer Institute
Summary
This research study is evaluating a genomic analysis called Predictor Analysis of Microarray 50 (PAM50, by Prosigna®) as a tool to possibly guide the participant and the treating physician to choose the most personalized pre-operative treatment for breast cancer.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2019-03-21
Completion Date
2025-08-10
Last Updated
2026-09-30
Healthy Volunteers
No
Conditions
Interventions
Prosigna PAM-50 assay
Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery
Locations (1)
Dana-Farber Cancer Institute
Boston, Massachusetts, United States